Compare BW & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | BEAM |
|---|---|---|
| Founded | 1867 | 2017 |
| Country | United States | United States |
| Employees | 1650 | N/A |
| Industry | Building Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | N/A | 2019 |
| Metric | BW | BEAM |
|---|---|---|
| Price | $18.99 | $28.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $8.00 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 3.7M | 2.0M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $41.58 | N/A |
| Revenue Next Year | $66.70 | $33.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $0.67 | $15.60 |
| 52 Week High | $22.03 | $36.44 |
| Indicator | BW | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 54.84 | 48.66 |
| Support Level | $13.54 | $28.50 |
| Resistance Level | $22.03 | $29.06 |
| Average True Range (ATR) | 1.95 | 1.97 |
| MACD | 0.15 | -0.48 |
| Stochastic Oscillator | 61.43 | 32.57 |
Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.